Coherus BioSciences (NASDAQ:CHRS) Earns Buy Rating from HC Wainwright

Coherus BioSciences (NASDAQ:CHRS)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $7.00 target price on the biotechnology company’s stock. HC Wainwright’s price target would indicate a potential upside of 434.35% from the company’s previous close.

Several other equities analysts have also weighed in on CHRS. StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Robert W. Baird lifted their target price on shares of Coherus BioSciences from $4.00 to $6.00 and gave the company an “outperform” rating in a report on Thursday, December 5th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Trading Down 0.8 %

Shares of NASDAQ CHRS opened at $1.31 on Thursday. Coherus BioSciences has a 12 month low of $0.66 and a 12 month high of $2.87. The company has a 50 day simple moving average of $1.40 and a two-hundred day simple moving average of $1.27. The stock has a market cap of $150.93 million, a price-to-earnings ratio of -16.38 and a beta of 0.82.

Institutional Investors Weigh In On Coherus BioSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Steph & Co. purchased a new stake in Coherus BioSciences in the 4th quarter worth $34,000. Systematic Financial Management LP purchased a new stake in Coherus BioSciences in the 3rd quarter worth $28,000. Hsbc Holdings PLC increased its holdings in Coherus BioSciences by 10.6% in the 2nd quarter. Hsbc Holdings PLC now owns 103,183 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 9,905 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Coherus BioSciences by 19.5% during the second quarter. Rhumbline Advisers now owns 154,904 shares of the biotechnology company’s stock worth $268,000 after buying an additional 25,241 shares in the last quarter. Finally, FMR LLC grew its holdings in shares of Coherus BioSciences by 21.1% during the third quarter. FMR LLC now owns 225,113 shares of the biotechnology company’s stock worth $234,000 after buying an additional 39,204 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Coherus BioSciences Company Profile

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.